The Quantellect read.As of Nov 19, 2026, 8 active firms cover Disc Medicine Inc: 8 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $92.00 to $170.00, a moderate spread. The average target of $120.13 sits 54% above the current $77.93. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.63 next quarter toward $-6.25 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy8100%
Neutral00%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$120.13
+54.1% upside
Average target across 8 active firms as of Nov 19, 2026 vs $77.93 current
Highest Target$170.00
Average Target$120.13
Lowest Target$92.00
Detailed analyst forecasts for IRON
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 8 of 8 active firms rate IRON a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IRON EPS & revenue forecast
EPS · NEXT QUARTER
$-1.63
Range $-1.91 – $-1.45 · 7 analysts · -1% YoY
Next period, 7 analysts expect Disc Medicine Inc. to earn $-1.63 a share (range $-1.91 – $-1.45), versus $-1.65 a year earlier. Full-year consensus is $-6.03, growing to $-6.25 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $43.2M next year.
Top analysts covering Disc Medicine Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IRON.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Buy
$85.00+9.1% to target
Overall win rate
64%
+ Follow
#2
David Nierengarten
Wedbush · Rank #24
Buy
$110.00+41.2% to target
Overall win rate
48%
+ Follow
#3
Roger Song
Jefferies · Rank #122
Buy
$154.00+97.6% to target
Overall win rate
43%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Buy
$75.00-3.8% to target
Overall win rate
38%
+ Follow
#5
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$170.00+118.1% to target
Overall win rate
38%
+ Follow
IRON stock forecast FAQ
What is IRON's average 12-month price target?+
The 8 active firms with a live target average $120.13 for Disc Medicine Inc. over the next 12 months, ranging from a $170.00 high to a $92.00 low, as of Nov 19, 2026.
Is IRON stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 8 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IRON?+
The Street-high target is $170.00 (Cantor Fitzgerald), and the Street-low is $92.00 (Morgan Stanley). The average of all 8 active-firm targets is $120.13.
How many active Wall Street firms cover IRON?+
8 active firms have a recognized rating on Disc Medicine Inc. as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IRON?+
Among analysts who currently cover IRON, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Buy with a $85.00 target.
What is Disc Medicine Inc.'s projected EPS for next quarter?+
The consensus estimate is $-1.63 per share (range $-1.91 – $-1.45) across 7 analysts. Full-year EPS is projected at $-6.03, rising to $-6.25 the following year.
How much revenue is Disc Medicine Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $43.2M next year.
Have analysts been upgrading or downgrading IRON lately?+
As of Nov 19, 2026, 8 of 8 active firms rate IRON a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IRON calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.